Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

XLRN / Acceleron Pharma Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) ACCELERON PHARMA INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00434H108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

XLRN / Acceleron Pharma Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) ACCELERON PHARMA INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00434H108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

Celgene In 2018: A Look At The Long Thesis

2018-02-13 seekingalpha
The company is posturing for a transition to a time and place without patent protections on Revlimid. (61-0)

XLRN / Acceleron Pharma Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 7 ACCELERON PHARMA INC COMMON STOCK Cusip #00434H108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00434H108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,439,200 Item 6: 0 Item 7: 5,106,687 Item 8: 0 Item 9: 5,106,687 Item 11: 11.

XLRN / Acceleron Pharma Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 7 ACCELERON PHARMA INC COMMON STOCK Cusip #00434H108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00434H108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,439,200 Item 6: 0 Item 7: 5,106,687 Item 8: 0 Item 9: 5,106,687 Item 11: 11.

XLRN / Acceleron Pharma Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
acceleronpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Acceleron Pharma Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  00434H108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)

XLRN / Acceleron Pharma Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
acceleronpharmainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Acceleron Pharma Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  00434H108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)

Cue Biopharma: Too Early For This Very Exciting Platform

2018-02-06 seekingalpha
Cue Biopharma is a recent IPO which is looking to address HPV related cancers via interleukin-2 (IL-2), activation of nascent T-cells (not CAR-T) and modulation of autoimmune systems using a novel technology which does not include overall immune suppression. Although their December 27th IPO was well received, grossing $66.2 million at a price of $7.50/share this was just the start for Cue. In the ensuing weeks the shares have almost doubled on the back of a strong biotech rally and general anticipation about immune modulation as it relates to cancer. (34-3)

XLRN / Acceleron Pharma Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us00434h1086_011818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ACCELERON PHARMA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 00434H108 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------

XLRN / Acceleron Pharma Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-23 sec.gov
us00434h1086_011818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ACCELERON PHARMA INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 00434H108 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------

Acceleron Pharma: Updates To Thesis

2018-01-15 seekingalpha
I continue to look favorably on their collaboration with Celgene allowing them to take advantage of the larger firm´s considerable resources. (2-0)

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

2018-01-08 reuters
* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018 (2-0)

XLRN / Acceleron Pharma Inc. 8-K (Current Report)

2018-01-08 sec.gov
Document           UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  January 8, 2018   ___________________________   ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation)   001-36065 (Commission File Number)   27-0

Your Daily Pharma Scoop: Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafgen Provides Update

2018-01-06 seekingalpha
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)

XLRN / Acceleron Pharma Inc. 8-K (Current Report)

2018-01-03 sec.gov
Document           UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  January 2, 2018   ___________________________   ACCELERON PHARMA INC. (Exact name of Registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation)   001-36065 (Commission File Number)   27-0


CUSIP: 00434H108